Skip to main content

Table 2 Mean (SD) of groups (experimental and control), mean (SD) difference within groups, and mean (95% CI) difference between groups for all outcomes

From: Long-term effect of additional rehabilitation following botulinum toxin-A on upper limb activity in chronic stroke: the InTENSE randomised trial

Outcome

Groups

Difference within groups

Difference between groups

 

Month 0

Month 12

Month 12 minus Month 0

Month 12 minus Month 0

Exp (n = 69)

Con (n = 71)

Exp (n = 65)

Con (n = 68)

Exp

Con

Exp minus Con

Goal attainment GAS (T-score)

N/A

N/A

41 (14)

41 (13)

N/A

N/A

0 (-5 to 5)

Upper limb activity BBT (blocks/s)

0.03 (0.09)

0.04 (0.09)

0.04 (0.12) n = 64

0.04 (0.10) n = 66

0.01 (0.05)

0.01 (0.06)

0.01 (-0.01 to 0.03)

Spasticity Tardieu Scale (0–4)

2.0 (0.8)

1.9 (0.8)

1.6 (0.7) n = 23

1.4 (0.7) n = 22

-0.5 (0.8)

-0.4 (0.9)

-0.1 (-0.6 to 0.4)

Wrist extension ROM (deg)

35 (40) n = 68

38 (31)

25 (40) n = 61

28 (33) n = 64

-11 (28)

-10 (29)

-1 (-11 to 9)

Grip strength MVC dynamometry (kg)

3.6 (4.3)

4.7 (5.9)

3.8 (4.9) n = 64

4.1 (4.8) n = 66

0.2 (3.0)

-0.1 (4.5)

0.3 (-1.1 to 1.6)

Pain 10-cm VAS (0–10)

1.9 (2.7)

1.9 (2.6)

1.1 (21)

1.1 (1.9)

-0.6 (2.5)

-0.9 (2.4)

0.3 (-0.6 to 1.2)

Burden of care CBS (0–16)

6.7 (4.3)

6.5 (3.3)

4.8 (4.0)

4.1 (3.8)

-2.0 (5.4)

-2.5 (4.4)

0.4 (-1.2 to 2.1)

Quality of life, EQ-5D

 Overall health (0 to 100)

65 (21)

62 (20)

67 (23)

64 (24)

3 (24)

3 (18)

-1 (-8 to 7)

  1. Exp experimental group, Con control group, GAS Goal Attainment Scale, BBT Box and Block Test, ROM range of motion, MVC maximum voluntary contraction, VAS visual analogue scale, CBS Carer Burden Scale, EQ-5D EuroQual-5D